Beam Therapeutics said additional data from its Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) support continued performance of its base-editing gene therapy candidate after one year. The company reported follow-up results in six patients, extending the durability profile for the approach. AATD is driven by a genetic deficiency in the SERPINA1 gene, and base editing is intended to convert disease-causing variants toward a protective genotype. The update is aimed at de-risking the durability question that often determines long-term value for gene editing products. Investors will be watching whether clinical endpoints and biomarker improvements remain stable over extended follow-up periods as the program advances.